Sol-Gel Technologies (SLGL) Other Accumulated Expenses (2017 - 2018)
Sol-Gel Technologies (SLGL) reported Other Accumulated Expenses of $43000.0 for Q4 2018, down 6.52% year-over-year from $46000.0 in Q4 2017, and down 6.52% quarter-over-quarter from $46000.0 in Q4 2017.
Sol-Gel Technologies (SLGL) Other Accumulated Expenses (2017 - 2018) Analysis & Trends
Sol-Gel Technologies (SLGL) has 2 years of Other Accumulated Expenses data on file, last reported at $43000.0 in Q4 2018.
- Other Accumulated Expenses for Q4 2018 came in at $43000.0, down 6.52% year-over-year; the trailing twelve-month figure through Dec 2018 was $43000.0 (down 6.52% YoY), and the FY2018 annual result was $43000.0, down 6.52% from the prior year.
- Other Accumulated Expenses slipped to $43000.0 in Q4 2018 per SLGL's latest filing, from $46000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $46000.0 in Q4 2017 and troughed at $43000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Sol-Gel Technologies | 207.80 Mn | 197.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 43,000.00 |
| Dec 31, 2017 | 46,000.00 |